Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and pimobendan

pyrazines has been researched along with pimobendan in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (57.14)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asanoi, H; Inoue, H1
Furukawa, Y; Iwasaki, A; Matsumori, A; Nakamura, T; Okada, I; Ono, K; Sasayama, S; Shioi, T1
Matsumori, A; Nose, Y; Ono, K; Sasayama, S; Sato, Y; Shioi, T1
Sasayama, S3
Matsumori, A; Nunokawa, Y; Sasayama, S1

Reviews

2 review(s) available for pyrazines and pimobendan

ArticleYear
Inotropic agents in the treatment of heart failure: despair or hope?
    Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6

    Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Cyclic AMP; Digitalis; Heart Failure; Humans; Plants, Medicinal; Plants, Toxic; Prognosis; Pyrazines; Pyridazines; Quinolines

1997
[Inotropic agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:5

    Topics: Adrenergic alpha-Agonists; Animals; Cardiotonic Agents; Clinical Trials as Topic; Digitalis Glycosides; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines

2003

Other Studies

5 other study(ies) available for pyrazines and pimobendan

ArticleYear
Positive inotropic agents: a double-edged sword for chronic heart failure.
    Internal medicine (Tokyo, Japan), 1996, Volume: 35, Issue:1

    Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines

1996
Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages.
    Life sciences, 1996, Volume: 59, Issue:10

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Animals; Cardiotonic Agents; Cell Line; Culture Media; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide Synthase; Nitrites; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines

1996
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Journal of molecular and cellular cardiology, 1996, Volume: 28, Issue:12

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Failure; Humans; Interleukin-1; Interleukin-6; Kinetics; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pyrazines; Pyridazines; Quinazolines; Quinolines; Tumor Necrosis Factor-alpha

1996
Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.
    Life sciences, 2000, Oct-06, Volume: 67, Issue:20

    Topics: Amrinone; Animals; Cardiotonic Agents; Colforsin; Cytokines; Humans; Interleukin-1; Luciferases; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2000
Inotropic agents and immune modulation.
    Cardiovascular drugs and therapy, 2002, Volume: 16, Issue:3

    Topics: Adjuvants, Immunologic; Animals; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Humans; Myocardium; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quality of Life; Quinolines; Time Factors

2002